Quantcast

Latest Eisai Co. Ltd. Stories

2013-01-11 02:20:01

Tokyo, Jan 11, 2013 - (JCN Newswire) - Eisai Co., Ltd. announced today the preliminary results of its global Phase III study (Study FAR 131, MORAb-003-004) of farletuzumab (MORAb-003), an investigational compound under development at its U.S. subsidiary, Morphotek, Inc., in patients with platinum-sensitive epithelial ovarian cancer in first relapse.The study was a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparative study of 1,100 patients with...

2012-10-25 09:20:04

Tokyo, Oct 25, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has signed a global agreement with Brazil's Fundacao Oswaldo Cruz ("Fiocruz") aimed at collaborations to develop new medicines and vaccines for malaria and neglected tropical diseases (NTDs).Under the global agreement, Eisai and Fiocruz will identify research development collaborations targeting Eisai compounds for indications of malaria and NTDs. For the first collaboration, it has been decided to begin studies on...

2012-09-25 04:20:08

Tokyo, Sept 25, 2012 - (JCN Newswire) - Eisai Co., Ltd. and Santen Pharmaceutical Co., Ltd. announced today that they have entered into an option agreement which grants Santen rights of evaluation and first negotiation for Eisai-owned compounds in the field of ophthalmology.Under the terms of the agreement, Eisai shall grant Santen the rights to evaluate the feasibility of developing compounds disclosed by Eisai for use in the ophthalmologic field within a certain period as well as the rights...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.